# TP53 Synthetic Lethality Pipeline — Detailed Chronology

**Competency Question (CQ14)**: How can we validate synthetic lethal gene pairs from Feng et al. (2022) and identify druggable opportunities for TP53-mutant cancers?

**Pipeline**: Fuzzy-to-Fact v1.0
**Date Range**: 2026-03-03 (spans two sessions due to context window limits)

---

## Session 1: Phases 1–6a (Pipeline Execution)

### Phase 1 — ANCHOR

- Resolved TP53 to HGNC:11998 via `hgnc_search_genes("TP53")` → `hgnc_get_gene(HGNC:11998)`
- Cross-references obtained: ENSG00000141510, UniProtKB:P04637, NCBIGene:7157, STRING:9606.ENSP00000269305
- Verified reference paper PMID:35559673 via `get_article_metadata("35559673")`
  - Feng X et al., "Genome-wide CRISPR screens using isogenic cells reveal vulnerabilities conferred by loss of tumor suppressors," *Science Advances* (2022)

### Phase 2 — ENRICH

- Resolved 7 additional genes (6 SL partners + 1 regulator):
  - **WEE1** → HGNC:12761 via `hgnc_search_genes` → `hgnc_get_gene`
  - **CHEK1** → HGNC:1925 via `hgnc_search_genes` → `hgnc_get_gene`
  - **PLK1** → HGNC:9077 via `hgnc_search_genes` → `hgnc_get_gene`
  - **MDM2** → HGNC:6973 via `hgnc_search_genes` → `hgnc_get_gene`
  - **PPM1D** → HGNC:9277 via `hgnc_search_genes` → `hgnc_get_gene`
  - **POLQ** → NCBIGene:10721 via `entrez_search_genes` → `entrez_get_gene` (HGNC fallback — short symbol returned wrong result)
  - **ATR** → NCBIGene:545 via `entrez_search_genes` → `entrez_get_gene` (HGNC fallback — short symbol collision)
- **USP28** was located during search but not fully enriched (documented as gap)
- Each gene annotated with Ensembl, UniProt, and Entrez cross-references

### Phase 3 — EXPAND

- **STRING PPI network**: Queried `string_search_proteins("TP53")` → `string_get_interactions(9606.ENSP00000269305)` with score ≥ 0.700
  - 15 high-confidence interactors returned
  - Top: SIRT1 (0.999), RPA1 (0.999), MDM2 (0.995), ATM (0.995), HDAC1 (0.993), SFN (0.989), EP300 (0.972), HSP90AA1 (0.909), CREBBP (0.909), PTEN (0.902)
- **WikiPathways**: Queried `wikipathways_get_pathways_for_gene(TP53)`
  - 295 total pathways returned
  - 4 selected for KG: WP1742 (TP53 network), WP1775 (Cell cycle checkpoints), WP3878 (ATM signaling), WP3565 (DNA Damage Senescence)
- **Open Targets disease associations**: Queried `opentargets_get_associations(ENSG00000141510)`
  - 3,277 total associations
  - Top 8 catalogued: Li-Fraumeni (0.876), HCC (0.796), HNSCC (0.777), hereditary breast (0.743), CRC (0.736), lung adeno (0.729), esophageal (0.728), AML (0.724)

### Phase 4a — CRISPR_VALIDATION (BioGRID ORCS)

- Queried `get_orcs_essentiality` for three candidate SL partners:
  - **WEE1** (Entrez 7465): 882 hit screens — broadly essential, G2/M checkpoint dependency
  - **CHEK1** (Entrez 1111): 928 hit screens — broadly essential, S-phase checkpoint
  - **PLK1** (Entrez 5347): 929 hit screens — broadly essential, core mitotic regulator (highest count)
- Note: ORCS data is pan-essential, not TP53-specific. SL specificity depends on Feng et al.'s isogenic design.
- PPM1D, POLQ, ATR not queried via ORCS (pipeline scope decision)

### Phase 4b — TRAVERSE_DRUGS (Open Targets knownDrugs)

- Queried Open Targets GraphQL `knownDrugs` endpoint via curl for 4 druggable targets:
  - **WEE1** (ENSG00000166483): Adavosertib (AZD1775), Phase 2
  - **CHEK1** (ENSG00000149554): Prexasertib (Phase 2), Rabusertib (Phase 2)
  - **PLK1** (ENSG00000166851): Volasertib (Phase 3), BI-2536 (Phase 2)
  - **MDM2** (ENSG00000135679): Idasanutlin (Phase 3), Navtemadlin (Phase 2)
- MDM2 antagonists flagged: require wild-type TP53, contraindicated in TP53-mutant cancers
- ATR and POLQ drug traversal NOT performed (documented as gap — known drugs berzosertib, ceralasertib, novobiocin not retrieved)

### Phase 5 — TRAVERSE_TRIALS (ClinicalTrials.gov)

- Discovered and validated 5 clinical trials via `clinicaltrials_search_trials` → `clinicaltrials_get_trial`:
  1. **NCT01164995** — Phase II, AZD1775 + carboplatin in TP53-mutant epithelial ovarian cancer, COMPLETED, TP53-specific ✓
  2. **NCT02448329** — Phase II, AZD1775 + paclitaxel in TP53-mutant gastric adenocarcinoma, COMPLETED, TP53-specific ✓
  3. **NCT02688907** — Phase II, AZD1775 monotherapy in TP53-mutant SCLC, TERMINATED, TP53-specific ✓
  4. **NCT02808650** — Phase I/II, Prexasertib in pediatric solid tumors, COMPLETED, all-comer
  5. **NCT02545283** — Phase III, Idasanutlin + cytarabine in R/R AML, TERMINATED (futility), requires TP53-WT
- All 5 NCT IDs independently validated
- 3/5 trials specifically enrolled TP53-mutant patients — all using adavosertib

### Phase 6 — VALIDATE

- Re-verified all 10 entities with external identifiers against source databases
- Validated 23 edges for biological consistency
- Key finding: MDM2 antagonist mechanism mismatch confirmed by NCT02545283 TP53-WT requirement
- Validation summary: 10 validated, 0 invalid, 0 unverifiable

### Phase 6a — PERSIST

- Serialized complete knowledge graph to `tp53-synthetic-lethality-kg.json`
  - 24 nodes: 8 genes, 7 compounds, 4 pathways, 5 trials
  - 23 edges: 5 SYNTHETIC_LETHAL, 2 REGULATES, 4 MEMBER_OF, 7 INHIBITOR, 5 TESTED_IN
  - Metadata includes: phases_completed, total_disease_associations (3277), total_string_interactions (15), total_pathways (295)
- Compounds use custom CURIEs (COMPOUND:ADAVOSERTIB) not CHEMBL CURIEs (documented as quality review finding)

---

## Session 1 (continued): `/ob-report` — Stage 1a Report Formatting

- Invoked `bio-research:biosciences-reporting` skill
- Read SKILL.md → selected **Template 1: Drug Discovery / Repurposing** based on CQ14 matching criteria
- Generated `tp53-synthetic-lethality-report.md` (208 lines, 17KB)

### Evidence Grading (11 claims)

| # | Claim | Final Score | Level |
|---|-------|-------------|-------|
| 1 | TP53-WEE1 SL + Phase II trials | 0.95 | L4 Clinical |
| 2 | WEE1 ORCS essentiality (882) | 0.60 | L2 Multi-DB |
| 3 | CHEK1 ORCS essentiality (928) | 0.60 | L2 Multi-DB |
| 4 | PLK1 ORCS essentiality (929) | 0.60 | L2 Multi-DB |
| 5 | Prexasertib/CHEK1 + Phase I/II | 0.80 | L3 Functional |
| 6 | Volasertib/PLK1 Phase 3 | 0.70 | L3 Functional |
| 7 | MDM2 antagonists contraindicated | 0.50 | L2 Multi-DB |
| 8 | TP53-MDM2 interaction (STRING 0.995) | 0.65 | L2 Multi-DB |
| 9 | POLQ SL (MMEJ dependency) | 0.35 | L1 Single-DB |
| 10 | ATR SL (replication stress) | 0.35 | L1 Single-DB |
| 11 | PPM1D DDR modulation | 0.50 | L2 Multi-DB |

- **Median**: 0.60 | **Range**: 0.35–0.95 | **Distribution**: 1×L4, 2×L3, 6×L2, 2×L1

---

## Session 1 (continued): `/ob-review` — Stage 2 Quality Review

- Invoked `bio-research:biosciences-reporting-quality-review` skill
- Evaluated against 10-dimension framework for Template 1
- Generated `tp53-synthetic-lethality-quality-review.md` (14.8KB)

### Quality Review Results

| Dimension | Score | Verdict | Notes |
|-----------|-------|---------|-------|
| CURIE Resolution | 8/10 | PARTIAL | Compounds lack CHEMBL IDs (presentation failure) |
| Source Attribution | 9/10 | PASS | All claims have [Source:] citations |
| LOCATE→RETRIEVE | 7/10 | PARTIAL | LOCATE steps executed but not explicitly cited (presentation failure) |
| Disease CURIE | 6/10 | PARTIAL | Diseases in separate section, not graph nodes (protocol gap + presentation) |
| OT Pagination | 9/10 | PASS | — |
| Evidence Grading | 10/10 | PASS | All 11 claims with modifiers and final scores |
| GoF Filter | 9/10 | PASS | MDM2 mismatch correctly flagged |
| Trial Validation | 10/10 | PASS | All 5 NCT IDs verified |
| Completeness | 9/10 | PASS | 7 gaps documented |
| Hallucination Risk | 9/10 | PASS (LOW) | No entities introduced from training knowledge |

- **Overall**: PASS | Protocol: 8/10 | Presentation: 8/10
- 7 PASS, 3 PARTIAL, 0 FAIL

---

## Session 1 → Session 2: `/ob-publish` — Full Publication Pipeline

### Stage 1a (reused)
- Report already exists from `/ob-report` → no regeneration needed

### Stage 1b — Synapse Dataset Grounding
- Executed 6 Synapse searches with compound queries (gene+disease first, single-term fallback)
- Two queries returned HTTP 500 errors (worked around with alternative queries)
- One result set too large (139KB) — parsed via python3 JSON extraction

### Synapse Datasets Found

| Synapse ID | Name | Strength | Coverage |
|-----------|------|----------|---------|
| syn2384331 | Broad-DREAM Gene Essentiality Prediction Challenge | Moderate | WEE1, CHEK1, PLK1 |
| syn5889324 | Cancer Cell Line Encyclopedia (CCLE) | Moderate | TP53, WEE1, CHEK1, PLK1 |
| syn21641955 | NF1 Synthetic Lethality Investigation | Analogous | Methodology only |
| syn274455 | TCGA Ovarian Serous Cystadenocarcinoma | Moderate | TP53 disease association |
| syn53480749 | Cell Signaling and Drug Therapy | Weak | Pathway context |

- **Node coverage**: 21% (5/24) | **Edge coverage**: 16% (3/19 groundable)
- No evidence level upgrades warranted
- Generated `tp53-synthetic-lethality-synapse-grounding.md` (8.4KB)

### Stage 2 (reused)
- Quality review already exists from `/ob-review` → no regeneration needed

### Stage 3 — BioRxiv Manuscript Draft (Session 2)
- Generated `tp53-synthetic-lethality-biorxiv-draft.md` (32KB) in IMRaD format:
  - **Abstract**: ~340 words covering background, methods, results, conclusions
  - **Introduction**: ~650 words covering TP53 biology, synthetic lethality concept, Feng et al. findings, Fuzzy-to-Fact rationale
  - **Methods**: 4 subsections — Pipeline Architecture (8 phases), Evidence Grading (L1-L4 system), Synapse Grounding, Quality Review
  - **Results**: 9 subsections — Entity Resolution, CRISPR Validation, Drug Candidates, Clinical Trials, Evidence Assessment, PPI Network, Pathway Context, Disease Associations, Synapse Grounding
  - **Discussion**: 4 subsections — WEE1 as top target, Checkpoint kinase complementarity, MDM2 mechanism mismatch, Limitations/Future
  - **References**: 15 numbered references with tool call provenance
  - **Supplementary**: Tables S1 (24 nodes), S2 (23 edges), S3 (11 evidence grades), S4 (5 Synapse datasets)

### Stage 4 — Verification Checklist (Session 2)
- Ran 8 automated checks:

| Check | Result |
|-------|--------|
| 1. File existence (5/5 files) | PASS |
| 2. JSON validity (24 nodes, 23 edges) | PASS |
| 3. Node count consistency (24 across all files) | PASS |
| 4. Edge count consistency (23 across all files) | PASS |
| 5. Synapse dataset consistency (5 syn IDs) | PASS |
| 6. Disease CURIE consistency (4 common IDs) | PASS |
| 7. NCT ID consistency (5/5 match) | PASS |
| 8. No API keys or secrets | PASS |

---

## Final File Inventory

| File | Size | Stage | Description |
|------|------|-------|-------------|
| `tp53-synthetic-lethality-kg.json` | 16.9KB | Phase 6a | Knowledge graph (24 nodes, 23 edges) |
| `tp53-synthetic-lethality-report.md` | 17.1KB | Stage 1a | Template 1 report with evidence grading |
| `tp53-synthetic-lethality-synapse-grounding.md` | 8.4KB | Stage 1b | 5 Synapse datasets mapped to KG |
| `tp53-synthetic-lethality-quality-review.md` | 14.9KB | Stage 2 | 10-dimension quality review (PASS) |
| `tp53-synthetic-lethality-biorxiv-draft.md` | 32.2KB | Stage 3 | IMRaD manuscript with supplements |

**Total output**: ~89.5KB across 5 files

---

## Key Decisions and Findings

1. **WEE1 inhibition (adavosertib) is the most clinically validated SL target** — only target with TP53-specific Phase II trials (L4, 0.95)
2. **MDM2 antagonists correctly excluded** — require wild-type TP53; −0.20 mechanism mismatch applied
3. **BioGRID ORCS shows pan-essentiality, not TP53-specificity** — 882-929 hit screens reflect broad dependency; SL differential from Feng et al. isogenic design
4. **ATR and POLQ are promising but under-validated** — L1 evidence (0.35) due to single-source (reference paper only); known drugs not retrieved because drug traversal was not performed for these targets
5. **Synapse grounding is moderate** — Feng et al. CRISPR data on GEO/SRA, not Synapse; strongest grounding from DREAM/CCLE datasets
6. **HGNC fallback to Entrez for short symbols** — ATR and POLQ required Entrez resolution due to HGNC fuzzy search limitations

---

## Databases and Tools Used

| Database | Tool(s) | Purpose |
|----------|---------|---------|
| HGNC | hgnc_search_genes, hgnc_get_gene | Gene resolution (6 genes) |
| NCBI Entrez | entrez_search_genes, entrez_get_gene | Gene resolution fallback (2 genes) |
| PubMed | get_article_metadata | Reference paper verification |
| STRING v12 | string_search_proteins, string_get_interactions | PPI network (15 interactors) |
| WikiPathways | wikipathways_get_pathways_for_gene | Pathway context (4 pathways) |
| BioGRID ORCS | get_orcs_essentiality | CRISPR validation (3 genes) |
| Open Targets | opentargets_get_associations, curl GraphQL | Disease associations + knownDrugs |
| ClinicalTrials.gov | clinicaltrials_search_trials, clinicaltrials_get_trial | Trial discovery + validation (5 NCTs) |
| Synapse.org | search_synapse, get_entity | Dataset grounding (5 datasets) |
